Previous close | 0.0600 |
Open | 0.1400 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 135.00 |
Expiry date | 2023-10-20 |
Day's range | 0.0500 - 0.1400 |
Contract range | N/A |
Volume | |
Open interest | 1.69k |
Brussels is negotiating a new Covid-19 vaccine procurement deal with US drugmaker Moderna as EU health authorities grow concerned about a rise in coronavirus infections. The deal is being negotiated between Brussels and the Boston-based biotechnology group, two people familiar with the matter said, with member states able to confirm their interest on an individual basis. At least eight EU countries were interested in opting into a new supply deal, one of the people said, adding that the contract was specifically for messenger ribonucleic acid-based Covid-19 vaccines.
The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.